JTT-662 / Japan Tobacco - LARVOL DELTA

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: Akros Pharma Inc.; Recruiting ➔ Completed

Clinical • Monotherapy • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Akros Pharma Inc.; Trial completion date: Nov 2020 ➔ Mar 2021; Trial primary completion date: Nov 2020 ➔ Mar 2021

Clinical • Monotherapy • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Akros Pharma Inc.

Clinical • Monotherapy • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus